Tarsus bets USD 565 million to displace Betadine in intravitreal injection prep

Irvine, California-based Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) [has acquired ](https://www.globenewswire.com/news-release/2026/07/08/3324437/0/en/Tarsus-Advances-Eye-Care-Leadership-Strategy-with-Acquisition-of-iRenix-Medical-and-Late-Stage-Asset-IRX-101.html)iRenix Medical, Inc., a privately held clinical-stage ophthalmic biopharmaceutical company, in a deal structured to bring IRX-101, an investigational ocular antiseptic, into Tarsus's US ophthalmology pipeline. The acquisition signals Tarsus's strategic pivot beyond its commercially established Demodex blepharitis franchise into the retinal disease space, where more than 11 million intravitreal injections are performed annually in the US. The deal carries an upfront consideration of approximately USD 75 million, split equally between USD 37.5 million in cash and USD 37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to USD 490 million, bringing the total potential deal value to approximately USD 565 million. No royalty terms or individual milestone tranches were disclosed. Geographic scope was not specified, though the acquisition is structured as a full company purchase of iRenix Medical with no disclosed carve-outs. IRX-101 is a stable aqueous chlorine dioxide solution formulated for topical ocular surface application as a pre-procedural antiseptic for intravitreal injections. It is designed to replace 5% povidone-iodine (Betadine), which has served as the standard of care for ocular surface sterilization prior to intravitreal procedures for more than four decades. IRX-101's mechanism — broad-spectrum antimicrobial activity via chlorine dioxide on the ocular surface — does not involve intravitreal delivery and is applied topically before injection. The drug successfully completed the [Phase 2b/3 RELIEF trial](https://app.allsci.com/clinical-trial/ASC-CT-0000000169970-1.0-1745775348), and based on data from that study and FDA feedback Tarsus plans to initiate a confirmatory Phase III safety and tolerability study in H1 2027. The deal extends Tarsus's eye care strategy beyond its lead commercial product, XDEMVY (lotilaner ophthalmic solution 0.25%), which is FDA-approved for Demodex blepharitis and generated USD 451.4 million in net product sales in 2025. The company entered the iRenix acquisition with approximately USD 388.7 million in cash, cash equivalents, and marketable securities as of Q1 2026. The mixed cash-and-stock consideration structure preserves balance sheet flexibility while aligning deal economics with IRX-101's regulatory and commercial milestones. For Tarsus, the acquisition establishes a presence in the retina subspecialty — a commercially distinct channel from the anterior segment and lid disease specialists who prescribe XDEMVY — and provides a near-term regulatory catalyst with Phase III data expected in 2028. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/irx-101-intravitreal-injection-tarsus-bets-usd)